Date:2024-07-10
Authors:Lisa A Beck 1, Robert Bissonnette2, Mette Deleuran3, Takeshi Nakahara4, Ryszard Galus5, Anna Coleman6, Guy Gherardi7, Jing Xiao8, Robert Dingman8, Christine Xu9, Elena Avetisova8, Ariane Dubost-Brama10, Arsalan Shabbir8
Category: Dermatitis (all types)
Importance: Moderate to severe atopic dermatitis (AD) is a chronic inflammatory skin disease that often requires continuous long-term systemic management. Long-term safety and efficacy data for treatment options are critically important.
Objective: To assess the safety and efficacy of dupilumab treatment for up to 5 years in adults with moderate to severe AD.